Improving the profiles of medicines with transdermal technology
A biotechnology company focused on improving the profiles of medicines through its proprietary permeation enhanced transdermal technology (PETT).
The platform technology uniquely combines high flux and sustained release into a matrix drug in adhesive patch. Our initial focus is on cancer and supportive care, developing transdermal patches to improve the lives of those affected by cancer.
The company is reformulating existing medicines that are well characterized and have a long and robust medical history. As result, ChemioCare will be able to leverage the 505(b)2 regulatory path, enabling:
a shortened development timeline,
and significantly reduced financial investment
Cancer and Cancer Supportive Care Focus.
The company is using a lean development approach in a focused therapeutic area to maximize value creation opportunities. There is an exciting opportunity to expand into additional therapeutic areas after accelerating the supportive care products to market.
Our internal team and scientific advisors have a deep understanding of the unmet need in cancer and cancer supportive care, the opportunities for our transdermal platform to address those unmet needs. The team has extensive clinical development experience.
At ChemioCare our goal is to have a positive impact on the lives of patients and families impacted by cancer by developing products that build on the current treatment paradigm safely and effectively.